LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects

LTX-315 is an oncolytic peptide that has antitumor efficacy in mice grafted with various tumor cell lines and is currently being tested in phase II clinical trials. Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Hsin-Wei, Garris, Christopher, Pfirschke, Christina, Rickelt, Steffen, Arlauckas, Sean, Siwicki, Marie, Kohler, Rainer H., Weissleder, Ralph, Sundvold-Gjerstad, Vibeke, Sveinbjørnsson, Baldur, Rekdal, Øystein, Pittet, Mikael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shared Science Publishers OG 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859426/
https://www.ncbi.nlm.nih.gov/pubmed/31799501
http://dx.doi.org/10.15698/cst2019.11.204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859426/
https://www.ncbi.nlm.nih.gov/pubmed/31799501
http://dx.doi.org/10.15698/cst2019.11.204

Ejemplares similares